Management ChangeJun 4, 2026, 04:13 PM
Nyxoah SA Initiates Search for U.S.-Based CEO
AI Summary
Nyxoah SA announced a leadership transition, initiating a search for a U.S.-based Chief Executive Officer to accelerate its U.S. commercial growth. Current CEO Olivier Taelman will remain engaged during the transition. The company also provided updates on its liquidity, reporting 25.9 million in cash and equivalents as of March 31, 2026, with a cash runway into Q3 2026. Additionally, Nyxoah detailed the conclusion of its collaboration with Cochlear Limited, ongoing patent litigation with Inspire Medical Systems, and positive commercial progress in both Europe and the U.S.
Key Highlights
- Nyxoah SA announced a leadership transition to appoint a U.S.-based CEO to accelerate U.S. commercial traction.
- Olivier Taelman will remain CEO during the transition period to ensure a smooth handover.
- As of March 31, 2026, Nyxoah had cash, cash equivalents, and financial assets of 25.9 million.
- The company reported an accumulated deficit of 321.7 million as of March 31, 2026.
- Cash runway is expected to extend into Q3 2026, considering the EIB loan facility.
- Collaboration and license agreements with Cochlear Limited have ended as all work is completed.
- Nyxoah is involved in ongoing patent infringement lawsuits with Inspire Medical Systems in the US and Germany.
- Over 1,000 patients treated with Genio system in Europe; 91 active accounts in the US, a 60% increase QoQ.
Price Impact
More from NYXH